Market Exclusivity Decision Pending For Bayer’s First-In-Class OTC Switch Astepro Allergy

 
• By Malcolm Spicer
  
Astepro Allergy labeling was approved with Bayer's NDA for an OTC switch of azelastine hydrochloride nasal spray. • Source: FDA

More from Regulation

More from Policy & Regulation